- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06390657
Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors (S-C-PATHY)
Study Overview
Detailed Description
This study will be conducted as a two phase study. Phase A is a retrospective study. Up to 10 patients with bulky (>6cm tumors) previous planned with planning CT with IV contrast will be selected for planning and dosimetry comparison. This is performed to optimize the contouring and planning procedures. Phase B is a prospective study. Ten patients with bulky (>6cm tumor) requiring radiotherapy, with planning CT and MR with IV contrast will be accrued. Every effort will be made to include equal numbers of patients (2-3) from head and neck, thorax, abdomen and pelvis. Their images will be used for planning and dosimetry comparison.
Patients will be treated according to clinical plans. The study plans will not be used for treatment. Treatment plans for Photon delivery (SBRT-PATHY) and Carbon delivery (CARBON-PATHY) to deliver 30 Gy in three fractions will be planned to be delivered to the BTV will be performed. SBRT-PATHY plans will be generated at the Princess Margaret Cancer Center (PMCC, Toronto, Canada) while CARBON-PATHY plans will be generated at the MedAustron Center for Particle Therapy and Research (W. Neustadt, Austria).
The objective is to compare the dosimetric profile achievable using SBRT-PATHY (using photons) and CARBON-PATHY (using carbon-ions) for unresectable bulky tumors and surrounding tissues.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Slavisa Tubin, M.D.
- Phone Number: 401 +43 2622 26 100
- Email: slavisa.tubin@medaustron.at
Study Locations
-
-
Niederösterreich
-
Wiener Neustadt, Niederösterreich, Austria, 2700
- EBG MedAustron GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Written informed consent (for use their planning CT and MR data for study specific planning)
- Malignant solid bulky primary or recurrent tumor with diameter of ≥6 cm
- Age > 18 years
- Radiation planning CT (with IV contrast) and MRI (with or without IV contrast) is planned
Exclusion Criteria:
- Patients without bulky lesions,
- Contraindication to i.v. CT and MRT contrast medium administration, particularly estimated glomerular filtration rate (GFR) less than 45 mL/min/1.73 m².
- Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control,
- Any condition that, in the opinion of the investigators, would interfere with treatment planning or interpretation of study results
Note (1): criterion n°4 will be evaluated on the four eyes principle, evaluated by both Principle Investigator and Sub-Investigators.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Phase A: retrospective planning study
Simulation CTs of up to ten patients with bulky (>6cm) tumors will be selected.
This will be used for optimization of contouring and planning strategy.
|
SBRT-PATHY and CARBON-PATHY planning is performed for study purposes only. Patients will be treated according to standard radiotherapy as per institutional policies. The planning images (CT, MRI) will be anonymized and used for planning purposes only. |
Phase B: prospective planning study
Ten patients with bulky tumors (>6cm) recommended to receive RT with CT and MRI planning will be accrued.
MRI DCE sequence (20-30mins) will be added if not requested for clinical use.
They will be treated with standard clinical plans.
Every effort will be made to include equal numbers of patients (2-3) from head and neck, thorax, abdomen and pelvis.
Planning images will be used for the purpose of dosimetric comparison between SBRT-PATHY and CARBON-PATHY radiation plans.
|
SBRT-PATHY and CARBON-PATHY planning is performed for study purposes only. Patients will be treated according to standard radiotherapy as per institutional policies. The planning images (CT, MRI) will be anonymized and used for planning purposes only. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase A: optimization of contouring and planning using PATHY strategy
Time Frame: 18 months (phase A and B combined)
|
The objective of phase A is to optimize the target delineation, planning strategy and techniques for SBRT-PATHY at Princess Margaret and CARBON-PATHY at MedAustron.
|
18 months (phase A and B combined)
|
Phase B: optimal coverage of Bystander tumor volume (BTV) while allowing the maximal radiation-sparing of PIM and regional lymph nodes
Time Frame: 18 months (phase A and B combined)
|
a prospective identification of 10 patients who are recommended to receive radiotherapy fulfilling the inclusion criteria.
SBRT-PATHY and CARBON-PATHY planning is perfomed for study purposes only.
A planning comparison between SBRT-PATHY (using photons) and CARBON-PATHY (using carbon-ions) based on dosimetric consideration achieved for the targeted BTV, non-targeted surrounding NTV (normoxic tumor segment), PIM, regional metastases (i.e.
local regional involved nodes and distant metastases located within 15 cm cranial caudal to GTV), regional uninvolved lymph nodes and surrounding organs at risk (OAR) will be performed.
|
18 months (phase A and B combined)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase B: Dosimetric-sparing of normoxic tumor volume (NTV)
Time Frame: 18 months (phase A and B combined)
|
The normoxic tumor segment (NTV) will be created by subtracting the BTV from the GTV, representing the remaining peripheral tumor segment outside the BTV.
|
18 months (phase A and B combined)
|
Phase B: Dosimetric-sparing of Organs at risk (OAR) and regional nodes
Time Frame: 18 months (phase A and B combined)
|
The OAR will be delineated on MRT images at the level of the treated area.
Particularly normal structures involved by or in the close proximity to the tumor such as vessels, nerves, or hollow organs will be contoured.
Contours will be checked and refined on the co-registered simulation CT images.
|
18 months (phase A and B combined)
|
Phase B: Feasibility for dosimetric-sparing of regional/distant metastases as abscopal tumor sites (if present)
Time Frame: 18 months (phase A and B combined)
|
Abscopal tumor site(s), corresponding to radiographic evidence of the regional (for ex.
lymph nodes) metastases, will be delineated on whichever images that clearly demonstrate their presence, including simulation CT or MRT.
|
18 months (phase A and B combined)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Slavisa Tubin, M.D., EBG MedAustron
- Principal Investigator: Rebecca Wong, MBChB, FRCPC, MSc, Prof., Princess Margaret Cancer Centre
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- S-C-PATHY-MA-122022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Planning CT, MRI
-
Royal Marsden NHS Foundation TrustCompletedBreast CancerUnited Kingdom
-
Cliniques universitaires Saint-Luc- Université...CompletedLiver Cancer | Ventilator Lung | Radiotherapy; Complications | Thoracic NeoplasmBelgium
-
Royal Marsden NHS Foundation TrustInstitute of Cancer Research, United KingdomUnknown
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RecruitingHead and Neck Cancer | Brain TumorUnited States
-
Lawson Health Research InstituteRecruitingAdvanced Cancer Requiring Palliative RadiationCanada
-
Institut Cancerologie de l'OuestRecruiting
-
University of LouisvilleJames Graham Brown Cancer CenterActive, not recruitingLung CancerUnited States
-
London Health Sciences CentreCompleted
-
Case Comprehensive Cancer CenterRecruitingSpine Metastases | Spine Stereotactic Radiosurgery (sSRS)United States